Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 15

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 15
---
 per share equal to 75%     
 of the lowest price per Ordinary Share during the first five trading days following the consummation of this offering;               
 and                                                                                                                                  |

| ● | Ordinary Shares                                                                                                                              
 underlying warrants issuable to the Company’s chief executive officer to                                                                     
 purchase such number of Ordinary Shares equal to two times the respective loan amount due to the Company’s chief executive officer,          
 based on a price per share equal to 75% of the lowest price per Ordinary Share during the first five trading days following the consummation 
 of this offering.                                                                                                                            |

Unless otherwise indicated, all information in this prospectus assumes or gives effect to:

| ● | no exercise of the Representative’s’ 
 over-allotment option;               |

| ● | no exercise of Representative’s 
 Warrants;                       |

| ● | the automatic conversion                                                                                                           
 of all outstanding preferred shares, par value NIS 0.01 per share of the Company, or the Preferred Shares, into 2,515,265 Ordinary 
 Shares, which will occur upon the completion of this offering.                                                                     |

| ● | the issuance of 609,888                                                                                                                    
 Ordinary Shares issuable upon the automatic conversion of the $900,000 outstanding principal amount of several convertible loan agreements 
 entered into between August 2020 and February 2021, or the 2020 CLAs, which will occur upon the completion of this offering; and           |

| ● | the issuance of 553,640                                                                                                                    
 Ordinary Shares issuable upon the automatic conversion of the $450,000 outstanding principal amount of several convertible loan agreements 
 entered into in October 2024, or the 2024 CLAs, which will occur upon the completion of this offering.                                     |

See “Description of Share Capital” for additional information.

<div align='center'>12</div>

SUMMARY FINANCIAL DATA The following table summarizes our financial data. We have derived the following statements of comprehensive loss for the years ended December 31, 2023 and 2022 and for the six months ended June 30, 2024 and 2023 and the balance sheet data as of June 30, 2024 from our audited financial statements as of December 31, 2023 and from our interim condensed financial statements as of June 30, 2024 included elsewhere in this prospectus. Such financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles, or U.S GAAP. In our opinion,